During CAR-T treatment, tumor necrosis factor-α (TNF-α) and IL1-β are secreted by activated bone marrow cells, which are the significant cytokines inducing endothelial activation [111] and aggravate the typical adverse reactions of CAR-T cell therapy, such as cytokine release syndrome (CRS) [112, 113]. The gene discussed is TNF; the disease is congenital rubella syndrome.